A double-blind clinical trial of kamalahar, an indigenous compound preparation, in acute viral hepatitis.

ABSTRACT

BACKGROUND: Kamalahar is an indigenous preparation reported to be beneficial in acute viral hepatitis. AIMS: To evaluate the efficacy of Kamalahain acute viral hepatitis in a double-blind, placebo-controlled study. METHODS: Fifty two patients with acute viral hepatitis were randomized to receive either Kamalahar 500 mg or a matched placebo three times a day for 15 days. Forty four patients (Kamalahar 20; placebo 24) completed the trial. RESULTS: Improvement in clinical signs was more marked with Kamalahar compared to placebo. The fall in serum bilirubin (p < 0.001), SGPT (p < 0.001) and serum alkaline phosphatase (p < 0.005) at day 15 was significantly greater with the drug. No significant side effects were observed. CONCLUSION: Kamalahar offers therapeutic promise in acute viral hepatitis.